AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16688429 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive posterior approach
Number of subjects: 152
Study 16688429 — intervention group
Group type: COMPARATOR
Intervention: Classic anterolateral approach
Number of subjects: 152
Study 12707230 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial injections of autologous mononuclear bone marrow cells (15 injections of 0.2 cc)
Number of subjects: 21
Study 12707230 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial injections of autologous mononuclear bone marrow cells
Number of subjects: 21
Study 12707230 — intervention group
Group type: COMPARATOR
Intervention: Control group (last 7 patients)
Number of subjects: 21
Study 11310908 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol EDTA
Number of subjects: 122
Study 11310908 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 122
Study 2206005 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 0.27 IU/kg (0.1 mg/kg) three times weekly for 6 months
Number of subjects: 95
Study 2206005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 2206005 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 95
Study 2206005 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment continued for another 6 months after initial treatment
Number of subjects: 95
Study 2206005 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of GH after 12 months of treatment
Number of subjects: 95
Study 7449300 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16
Study 7449300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 16
Study 7449300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30687503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) providing 600 kcal and 22 g protein a day
Number of subjects: 34
Study 30687503 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-meal snacks providing 600 kcal and 22 g protein a day
Number of subjects: 34
Study 27621045 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptives (LARCs)
Number of subjects: 987
Study 27621045 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-LARC prescription methods
Number of subjects: 987
Study 27621045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription methods/no method
Number of subjects: 987
Study 27621045 — intervention group
Group type: COMPARATOR
Intervention: LARCs
Number of subjects: 987
Study 27621045 — intervention group
Group type: COMPARATOR
Intervention: Weight perception
Number of subjects: 987
Study 27052067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg)
Number of subjects: 75
Study 27052067 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (10 μg/kg)
Number of subjects: 75
Study 27052067 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal saline)
Number of subjects: 75
Study 24583315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exertion-induced muscle injury and MT (n=15)
Number of subjects: 36
Study 24583315 — intervention group
Group type: EXPERIMENTAL
Intervention: MT only (n=11)
Number of subjects: 36
Study 24583315 — intervention group
Group type: COMPARATOR
Intervention: Exertion-induced muscle injury only (n=10)
Number of subjects: 36
Study 22180446 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional home physiotherapy visits of functional weight‐bearing exercises, functional task‐specific training
Number of subjects: 107
Study 22180446 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 107
Study 22180446 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional home physiotherapy visits
Number of subjects: 107
Study 21110174 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut-embedding therapy
Number of subjects: 65
Study 21110174 — intervention group
Group type: COMPARATOR
Intervention: Fufuchun Capsule (control)
Number of subjects: 65
Study 17425514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (200 mmol sodium daily)
Number of subjects: 0
Study 17425514 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet (20 mmol sodium daily)
Number of subjects: 0
Study 16366197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure at 12 degrees C for 180 minutes
Number of subjects: 0
Study 12160582 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional external irradiation with agonist analogue of gonadotropin-releasing hormone
Number of subjects: 405
Study 12160582 — intervention group
Group type: COMPARATOR
Intervention: Conventional external irradiation without agonist analogue of gonadotropin-releasing hormone
Number of subjects: 405
Study 11776800 — intervention group
Group type: EXPERIMENTAL
Intervention: NP regimen (NVB + PDD)
Number of subjects: 48
Study 11776800 — intervention group
Group type: EXPERIMENTAL
Intervention: NI regimen (NVB + IFO)
Number of subjects: 48
Study 7601292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha- and beta-adrenoceptor blocking agent
Number of subjects: 27
Study 2696207 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine solution infiltration anesthesia
Number of subjects: 40
Study 7040495 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 6
Study 7040495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31975288 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce sedentary behaviour (motivational interviewing, setting of behavioural goals)
Number of subjects: 35
Study 31975288 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce sedentary behaviour
Number of subjects: 35
Study 31975288 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 35
Study 31404581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral enucleation and resection of the prostate (B‐TUERP)
Number of subjects: 240
Study 31404581 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (B‐TURP)
Number of subjects: 240
Study 28245877 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 0
Study 28245877 — intervention group
Group type: COMPARATOR
Intervention: Enhanced financing (C1)
Number of subjects: 0
Study 28245877 — intervention group
Group type: COMPARATOR
Intervention: Pure control (C2)
Number of subjects: 0
Study 26732187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional education aimed at salt restriction to 6 g/d by nutritionists
Number of subjects: 95
Study 26732187 — intervention group
Group type: COMPARATOR
Intervention: Conventional salt‐restriction education
Number of subjects: 95
Study 25312265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.2 μg/kg, n = 24)
Number of subjects: 53
Study 23316559 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed approach with scaling/root planing (SRP)
Number of subjects: 0
Study 23316559 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed approach with laser-curettage/SRP
Number of subjects: 0
Study 23316559 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed approach with laser-curettage/SRP/laser-sealing
Number of subjects: 0
Study 23316559 — intervention group
Group type: COMPARATOR
Intervention: Open approach (papilla reflection/flap closure)
Number of subjects: 0
Study 19430821 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink/Syntac Classic (VSC)
Number of subjects: 60
Study 19430821 — intervention group
Group type: EXPERIMENTAL
Intervention: iCem (IC)
Number of subjects: 60
Study 19430821 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PAF)
Number of subjects: 60
Study 19430821 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RLX)
Number of subjects: 60
Study 19430821 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite (MCE)
Number of subjects: 60
Study 19430821 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental self-adhesive resin cement (EXP)
Number of subjects: 60
Study 18327605 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS(On)
Number of subjects: 7
Study 16339612 — intervention group
Group type: EXPERIMENTAL
Intervention: Any depression care
Number of subjects: 1175
Study 16339612 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-level depression care (antidepressant use or specialty counseling)
Number of subjects: 1175
Study 16339612 — intervention group
Group type: COMPARATOR
Intervention: Clinic percentage of Latino patients
Number of subjects: 1175
Study 12463661 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 455
Study 12463661 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 455
Study 12463661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 455
Study 10726430 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted MLSS velocity (trial 1)
Number of subjects: 10
Study 10726430 — intervention group
Group type: COMPARATOR
Intervention: 0.13 m sec-1 (4-8%) above predicted MLSS velocity (trial 2)
Number of subjects: 10
Study 8835247 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG glycosylation abnormalities in patients with RA
Number of subjects: 0
Study 8835247 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 2183112 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin-clindamycin
Number of subjects: 130
Study 2183112 — intervention group
Group type: COMPARATOR
Intervention: cefoxitin-doxycycline
Number of subjects: 130
Study 6139668 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine (3 micrograms of surface antigen) given at 0, 1, 2, and 5 months
Number of subjects: 401
Study 6139668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 31931932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.5‐3 mg/Kg body weight per day)
Number of subjects: 70
Study 31931932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 31273908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based diabetes prevention and management programme
Number of subjects: 20
Study 31273908 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual change processes (information provision, structuring and prioritizing health goals, action planning, self-monitoring, receiving feedback)
Number of subjects: 20
Study 31273908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group processes (common purpose, sharing experiences, social comparisons, monitoring and accountability, social support)
Number of subjects: 20
Study 31273908 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive group context (group cohesion, homogeneous group composition, positive group atmosphere)
Number of subjects: 20
Study 31273908 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal facilitation methods
Number of subjects: 20
Study 27765557 — intervention group
Group type: EXPERIMENTAL
Intervention: Talocrural mobilization with movement (MWM)
Number of subjects: 26
Study 27765557 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 26
Study 26224232 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antioxidant cream
Number of subjects: 10
Study 26224232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24479524 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis and three intradermal doses of aseptic, purified Plasmodium falciparum sporozoites.
Number of subjects: 1
Study 24479524 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (Malarone®) treatment initiated on day 11 post-CHMI.
Number of subjects: 1
Study 24479524 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up cardiac MRI at almost five months post-CHMI.
Number of subjects: 1
Study 22939581 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetected diabetics (HbA1c ≥6.5%)
Number of subjects: 626
Study 22939581 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetics (HbA1c <6.5%)
Number of subjects: 626
Study 22939581 — intervention group
Group type: COMPARATOR
Intervention: Known diabetics (HbA1c ≥6.5%)
Number of subjects: 626
Study 19716640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical active compression-decompression (ACD) CPR
Number of subjects: 126
Study 19716640 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR (Control)
Number of subjects: 126
Study 17761579 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater sitting height
Number of subjects: 10413
Study 17761579 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer legs
Number of subjects: 10413
Study 15037054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued key press task with instructed probabilities
Number of subjects: 0
Study 15037054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued key press task with a posteriori probabilities
Number of subjects: 0
Study 15037054 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory EEG negativity amplitudes
Number of subjects: 0
Study 15037054 — intervention group
Group type: COMPARATOR
Intervention: Overall task performance
Number of subjects: 0
Study 11465647 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 46
Study 11465647 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 46
Study 11465647 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (SR‐V)
Number of subjects: 46
Study 11465647 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 46
Study 9762658 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-enriched antibodies
Number of subjects: 55
Study 9762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected peptides
Number of subjects: 55
Study 7999195 — intervention group
Group type: EXPERIMENTAL
Intervention: New Pathway curriculum
Number of subjects: 121
Study 7999195 — intervention group
Group type: COMPARATOR
Intervention: Traditional curriculum
Number of subjects: 121
Study 3397807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination met‐hGH plus oxandrolone
Number of subjects: 70
Study 3397807 — intervention group
Group type: EXPERIMENTAL
Intervention: Met‐hGH alone
Number of subjects: 70
Study 3397807 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 70
Study 3397807 — intervention group
Group type: EXPERIMENTAL
Intervention: Met‐hGH
Number of subjects: 70
Study 31883847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with mucosal grass pollen allergen exposure
Number of subjects: 40
Study 29238967 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabasum 5 mg
Number of subjects: 0
Study 29238967 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabasum 20 mg
Number of subjects: 0
Study 29238967 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study 28931377 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy program augmented with mobile tele-health technology (6-10 total visits over 1 year)
Number of subjects: 75
Study 28931377 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy program augmented with mobile tele-health technology
Number of subjects: 75
Study 28931377 — intervention group
Group type: COMPARATOR
Intervention: Propensity score matched controls from the cohort study
Number of subjects: 75
Study 26437721 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink primes
Number of subjects: 0
Study 26437721 — intervention group
Group type: EXPERIMENTAL
Intervention: Masculinity norms
Number of subjects: 0
Study 26437721 — intervention group
Group type: COMPARATOR
Intervention: Distraction and placebo treatment
Number of subjects: 0
Study 24159345 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized ethanol extract (1% and 2%)
Number of subjects: 0
Study 24159345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21555314 — intervention group
Group type: EXPERIMENTAL
Intervention: Jetstream atherectomy device
Number of subjects: 172
Study 19058687 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid modified resin composite (Dyract eXtra)
Number of subjects: 24
Study 19058687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocomposite (Filtek Supreme)
Number of subjects: 24
Study 15998356 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g chitosan twice daily for 3 months
Number of subjects: 130
Study 15998356 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 3 months
Number of subjects: 130
Study 12706712 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent, intranasal, live attenuated influenza virus vaccine (LAIV)
Number of subjects: 4561
Study 10231910 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor digitorum accessorius longus (FDAL) presence in asymptomatic individuals
Number of subjects: 100
Study 10231910 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor digitorum accessorius longus (FDAL) appearance
Number of subjects: 100
Study 10231910 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor digitorum accessorius longus (FDAL) differentiation
Number of subjects: 100
Study 8665038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation counseling and metered-dose inhaler containing ipratropium bromide (two inhalations three times daily)
Number of subjects: 5733
Study 8665038 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 5733
Study 1852339 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed discussion on CPR (intervention group)
Number of subjects: 100
Study 1852339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no detailed discussion on CPR)
Number of subjects: 100
Study 6668225 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of ascorbate daily
Number of subjects: 2
Study 6668225 — intervention group
Group type: COMPARATOR
Intervention: Low intake of ascorbate
Number of subjects: 2
Study 30365922 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200-3000 mg/d)
Number of subjects: 89
Study 30365922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 29766596 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available mobile app-delivered mindfulness training (AMT)
Number of subjects: 112
Study 29766596 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WC)
Number of subjects: 112
Study 26708714 — intervention group
Group type: EXPERIMENTAL
Intervention: MIYCN-Intervention
Number of subjects: 5824
Study 26708714 — intervention group
Group type: COMPARATOR
Intervention: MIYCN-Control
Number of subjects: 5824
Study 26708714 — intervention group
Group type: COMPARATOR
Intervention: Comparison
Number of subjects: 5824
Study 26708714 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention
Number of subjects: 5824
Study 25123352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (0.9% diflurosilane) biannually
Number of subjects: 328
Study 25123352 — intervention group
Group type: COMPARATOR
Intervention: Placebo applications
Number of subjects: 328
Study 22526415 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic wound ring drapes (RD)
Number of subjects: 109
Study 22526415 — intervention group
Group type: COMPARATOR
Intervention: Control group without RD
Number of subjects: 109
Study 20026572 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 39
Study 20026572 — intervention group
Group type: COMPARATOR
Intervention: Walking outdoors
Number of subjects: 39
Study 16752587 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention during study
Number of subjects: 0
Study 16752587 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention during study
Number of subjects: 0
Study 16752587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast recognition judgments
Number of subjects: 0
Study 16752587 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow recognition judgments
Number of subjects: 0
Study 16752587 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-test congruence (picture size or speaker's voice)
Number of subjects: 0
Study 16752587 — intervention group
Group type: COMPARATOR
Intervention: Full attention
Number of subjects: 0
Study 16752587 — intervention group
Group type: COMPARATOR
Intervention: Divided attention
Number of subjects: 0
Study 14992000 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of sibutramine hydrochloride capsule
Number of subjects: 20
Study 14992000 — intervention group
Group type: COMPARATOR
Intervention: Reference sibutramine capsules
Number of subjects: 20
Study 10882858 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflouromethlyornithine (DFMO)
Number of subjects: 116
Study 10882858 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 116
Study 8742097 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 5 mu g/kg
Number of subjects: 45
Study 8742097 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 8 mu g/kg
Number of subjects: 45
Study 8742097 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 10 mu g/kg
Number of subjects: 45
Study 1524742 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-containing alloys
Number of subjects: 39
Study 1524742 — intervention group
Group type: COMPARATOR
Intervention: Non-zinc alloys
Number of subjects: 39
Study 3893778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 1 tablet
Number of subjects: 150
Study 3893778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 2 tablets
Number of subjects: 150
Study 3893778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 3 tablets
Number of subjects: 150
Study 3893778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (all doses)
Number of subjects: 150
Study 3893778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (3 tablets)
Number of subjects: 150